At Ryvu, we are dedicated to improving the lives of cancer patients. We understand the challenges faced by patients and their caregivers, and we are here to provide support, information and resources to help you navigate your journey.Ryvu is currently conducting clinical trials to treat patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndromes (HR-MDS), low-risk MDS and myelofibrosis. The study to treat patients with with DLBCL will initiate soon.
CLINICAL TRIALS
| Healthcare Provider | › | More information can be found below and in our clinical trials brochure: | › | Ryvu Clinical Brochure | |
| Patient | › | You should consult with your physician to discuss whether one of our studies is appropriate for you and the risks/benefits of entering a clinical study. For more information, please also see the links below. | |||
RIVER-52 |
AML and High Risk MDS | RVU120 | Now recruiting (more info) | |||
RIVER-81 |
AML | RVU120+venetoclax | Now recruiting (more info) | |||
REMARK |
Low Risk MDS | RVU120 | Now recruiting (more info) | |||
POTAMI-61 |
Myelofibrosis | RVU120 | Now recruiting (more info) | |||
JASPIS-01 |
r/r Aggressive B-cell Non-Hodgkin Lymphoma | RVU120 | Now recruiting (more info) |
Expert perspectives
| Hendrik Nogai, M.D. shares clinical and preclinical data on RVU120 | A.Falkowski, M.D.: Ryvu plans to launch the clinical study POTAMI-61 for patients with myelofibrosis | RVU120 clinical studies: CLI120 and RIVER-52 by D. Chraniuk, M.D. |
Key Research Areas
At Ryvu Therapeutics, we are conducting clinical trials to explore groundbreaking therapeutic candidates aimed at improving and extending the lives of patients with cancer. We discover and develop small molecule therapies aimed at safe and effective treatment of a variety of cancers. Our research pipeline employs diverse therapeutic approaches, including targeting transcriptional regulation, leveraging synthetic lethality, and utilizing immuno-oncology to offer new and effective treatment options.
 |
| Learn more |
| Other Online Resources | › | Leukemia and Lymphoma Society: resources for patients and caregivers Cancer.org: disease information across multiple cancers |
Study results are intended to satisfy public disclosure commitments and shall not be used for any other purpose. This information is not intended to promote or otherwise make any claims for any investigational or marketed products.
As a Sponsor of a clinical trial, we are unable to process patients’ personal data, especially medical data. All decisions regarding eligibility for participation in the study are made by independent research centers. It results from applicable legal regulations, including Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC and Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). The best step will be to contact the research center conducting the clinical trial directly.
Contact us
If you are a medical professional, an investigator for a Ryvu trial, or would like information about becoming an investigator, please contact us [email protected]